M. Oesterholt

Statistics

Publications

Citations

166

H-Index

Active since

2017

Affiliations

The Christie NHS Foundation Trust(Current)

Institut Jules Bordet

Royal Marsden Hospital

National Cancer Centre Singapore

Vall d'Hebron Hospital Universitari

M. Oesterholt is an author at The Christie NHS Foundation Trust specializing in oncology, metastatic her2-positive breast cancer, and metastatic breast cancer.

ORCID

Publications per year

2017–2024

Publications

LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer

C. Saura Manich, Joyce O’Shaughnessy, Philippe Aftimos et al. · Annals of Oncology · 2021 · 104 citations

Medicine, Oncology, Pharmacology +15

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)

Nicholas C. Turner, Cristina Saura, Philippe Aftimos et al. · Journal of Clinical Oncology · 2024 · 32 citations · Full text

Medicine, Oncology, Pharmacology +17

386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial

Philippe Aftimos, Nicholas C. Turner, Joyce O’Shaughnessy et al. · Annals of Oncology · 2023 · 18 citations · Full text

Medicine, Oncology, Breast Oncology +16

Abstract P6-12-02: SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer

P. G. Aftimos, C. Van Herpen, EC Mommers et al. · Cancer Research · 2017 · 12 citations

Medicine, Oncology, Pharmacology +17

1–4 of 4